Atossa Therapeutics, Inc. (ATOS): Free Cash Flow
-$29.79M
Year ended 2025-12-31
-$35.78M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$29.79M | n/m | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | -$21.05M | n/m | 2026-03-25, From 2024-01-01 |
| 2023-12-31 | -$20.95M | n/m | 2025-03-25, From 2023-01-01 |
| 2022-12-31 | -$20.79M | n/m | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | -$16.48M | n/m | 2023-03-22, From 2021-01-01 |
| 2020-12-31 | -$11.58M | n/c | 2022-02-28, From 2020-01-01 |
| 2019-12-31 | -$9.14M | n/m | 2021-03-31, From 2019-01-01 |
| 2018-12-31 | -$9.07M | n/a | 2020-03-26, From 2018-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Atossa Therapeutics, Inc. (ATOS) | 2025-12-31 | -$29.79M | n/m |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | -$17.63M | n/m |
| Unicycive Therapeutics, Inc. (UNCY) | 2025-12-31 | -$31.34M | n/m |
| Mereo BioPharma Group plc (MREO) | 2025-12-31 | -$30.99M | n/m |
| Medicinova Inc (MNOV) | 2025-12-31 | -$9.81M | n/m |
| NextCure, Inc. (NXTC) | 2024-12-31 | -$41.28M | n/m |
| BioXcel Therapeutics, Inc. (BTAIQ) | 2025-12-31 | -$57.62M | n/m |
| Hyperion Defi, Inc. (HYPD) | 2024-12-31 | -$30.28M | n/m |
| Actinium Pharmaceuticals, Inc. (ATNM) | 2025-12-31 | -$24.68M | n/m |
Compare ATOS, VRCA, UNCY, MREO side by side · Screen every company in Pharmaceutical Preparations ↗